Skip To Main Content
Pere Barba on Muck Rack

Pere Barba

As seen in: Color Research & Application, Nature, Wiley, Wiley Online Library, Dialnet - Universidad de La Rioja, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Pere

Contact Pere, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy

|
By Sergi Camarillas, Anna Alonso-Saladrigues, Víctor Navarro Verified, Júlia Marsal, Javier Delgado, Blanca Herrero, Claire Roddie, Veit Bücklein, Marion Subklewe, Mario Sánchez-Salinas, Ana Martin, Ana Martín, Anna Torrent, Antonio Pérez-Martínez, Gloria Iacoboni, Susana Rives, Pere Barba, Águeda Molinos, Alex Rampotas, Berta González-Martínez
| Nature Verified
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF. USD 39.95 Prices may be subject to local taxes which are calculated during checkout References Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al.
Open in Who Shared Issue with article?

Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party

|
By Gloria Iacoboni, Pere Barba, Irma Khvedelidze, Maud Ngoya, Paolo Corradini, Pierre Sesques, Marion Subklewe, Izaskun Zeberio, Alejandro Martín García-Sancho, Tom van Meerten, Robin Sanderson, Bertram Glass, Anna Sureda, Peter Dreger, Olivier Hermine, Ali Bazarbachi, Gilles Crochet, Jaroslaw Dybko
| Nature Verified
Chimeric antigen receptor T-cell therapy (CART) is a standard approach for patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) based on the ZUMA-2 and TRANSCEND NHL 001 trial results, which led to the regulatory approval of brexucabtagene autoleucel (brexu-cel) and lisocabtagene maraleucel (liso-cel), respectively [1, 2].
Open in Who Shared Issue with article?

CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis - Bone Marrow Transplantation

|
By Víctor Navarro Verified, Gloria Iacoboni, Cecilia Carpio, Samantha Feijóo, Francesc Bosch, Guillermo Villacampa, Pere Barba, Sergi Camarillas, Mario Sánchez-Salinas
| Nature Verified
Abstract Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL), with high remission rates across various CAR T-cell constructs. However, the durability of these responses remains a major challenge, with many patients experiencing relapse after an initial remission.
Open in Who Shared Issue with article?
See all 10 licensed articles (11 Total)